Shannon Connelly


Novel Frontline Regimen Improves PFS in Older Patients With MCL

February 21st 2019

The 4-drug combination of rituximab, bendamustine, bortezomib, and dexamethasone was found to improve progression-free survival and demonstrated a tolerable safety profile as frontline treatment for patients with mantle cell lymphoma who are ≥65 years.

PFS Benefit Confirmed With Daratumumab Plus VMP in Newly Diagnosed Myeloma

January 22nd 2019

Maria-Victoria Mateos, MD, PhD, discusses the updated findings from the ALCYONE trial in patients with newly diagnosed multiple myeloma.

BTK Inhibition Continues to Show Promise in Relapsed/Refractory MCL

January 15th 2019

Krish Patel, MD, discusses some of the most significant mantle cell lymphoma data presented during the 2018 ASH Annual Meeting and how the use of BTK inhibitors will evolve going forward.

Expert Highlights Assay to Determine Patients With Lung, Gastrointestinal Cancers to Receive Pembrolizumab

August 10th 2018

The PD-L1 immunohistochemistry 22C3 pharmDx can be an aid in identifying patients with non–small cell lung cancer and gastrointestinal cancers who are eligible for pembrolizumab (Keytruda) monotherapy.

Marshall Highlights Durable Benefits of Pembrolizumab in GI Cancers

May 3rd 2018

Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.

Naidoo Discusses Advances in the Management of Immunotherapy-Related AEs

March 13th 2018

Jarushka Naidoo, MBBCh, discusses some of the most commonly seen immune-related adverse events in patients with lung cancer and how to manage them.

Wakelee Discusses Debate Surrounding Osimertinib in Frontline EGFR-Mutant Lung Cancer

March 11th 2018

Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.

Findings Support Nab-Paclitaxel as Top Choice for First-Line TNBC Therapy

February 16th 2018

Hope S. Rugo, MD, discusses the importance of individualizing doses of nab-paclitaxel in triple-negative breast cancer.

Progression Issues Surface With NSCLC Immunotherapy

October 27th 2017

Paul A. Bunn Jr, MD, discusses strategies for analyzing and responding to signs of progression for patients receiving immunotherapy for non-small cell lung cancer.

Expert Discusses De-Escalation Difficulties, Other Topics in TNBC

August 13th 2017

Lisa Carey, MD, discusses the challenges with de-escalation in patients with TNBC and steps toward overcoming these obstacles.